OHCFF 财务： Light AI Inc AI 分析

主页

股票

OHCFF

财务数据

OHCFF 财务

Light AI Inc

$0.06

收盘价：Mar 24, 16:00:00 GMT-4

$0.06

盘后：Mar 24, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

OHCFF 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	08/31/2024	08/31/2023	08/31/2022	08/31/2021
营收	0	0	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	--
营收成本	--	--	--	--	--	--
毛利润	--	--	--	--	--	--
销售、一般及管理费用	9	3	1	0	0	0
研发	6	3	--	--	--	--
营业费用	21	7	1	0	0	0
其他非经营性收入 (费用)	0	0	0	0	0	0
税前利润	-21	-13	-1	0	0	0
所得税费用	--	--	--	--	--	--
净利润	-21	-13	-1	0	0	0
净利润增长	--	1,200%	--	--	--	-100%
稀释后流通股数	118.98	13.05	7.4	2.56	10.24	1.32
股份同比变动 (YoY)	--	76%	189%	-75%	675%	11%
每股收益 (摊薄)	-0.18	-1	-0.15	-0.02	0	-0.14
每股收益增长率	--	541%	482%	-891%	-102%	-97%
自由现金流	-14	-6	0	0	0	0
每股自由现金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
营业利润率	0%	0%	0%	0%	0%	0%
净利率	0%	0%	0%	0%	0%	0%
自由现金流利润率	0%	0%	0%	0%	0%	0%
EBITDA	-21	-7	--	--	--	0
EBITDA 利润率	0%	0%	--	--	--	0%
EBITDA 中的折旧与摊销	0	0	--	--	--	0
EBIT	-21	-7	-1	0	0	0
EBIT 利润率	0%	0%	0%	0%	0%	0%
有效税率	--	--	--	--	--	--

Follow-Up Questions

Light AI Inc 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Light AI Inc 的总资产为 $17，净损失为 $-13

OHCFF 的关键财务比率是什么？



Light AI Inc 的流动比率是 8.5，净利 margin 为 0，每股销售为 $0。

Light AI Inc 的收入按细分市场或地理位置如何划分？



Light AI Inc 最大收入来源是 Generic Medicine，在最近的收益报告中收入为 1,191,874,310。就地区而言， China 是 Light AI Inc 的主要市场，收入为 2,047,607,773。

Light AI Inc 是否盈利？



不，根据最新的财务报表，Light AI Inc 的净损失为 $-13

Light AI Inc 有负债吗？



是的，Light AI Inc 的负债为 2

Light AI Inc 的流通股有多少？



Light AI Inc 的总流通股为 113.47

关键数据

前收盘价

$0.0605

开盘价

$0.0624

当日区间

$0.0605 - $0.0696

52周范围

$0.042 - $0.55

交易量

35.0K

平均成交量

80.1K

股息收益率

每股收益（TTM）

-0.08

市值

$7.4M

什么是 LIGHT AI INC.？

Light AI Inc. is a technology company focused on developing artificial intelligence-based health screening and diagnostic solutions. The company is headquartered in Vancouver, British Columbia and currently employs 4 full-time employees. The company went IPO on 2025-01-08. The company is engaged in developing screening and diagnostic solutions aimed at improving healthcare delivery worldwide. The firm is developing a technology platform which represents the next generation of patient management that it applies AI algorithms to smartphone images, starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions, to identify the disease in seconds. Its app-based solution requires no swabs, lab tests or proprietary hardware of any kind. Its AI powered technology offers screening and diagnostic tools designed to address critical healthcare challenges. Its technology offers a significant advancement in the identification of GAS pharyngitis. Its approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin.

功能特性

资源